BRISTOL MYERS SQUIBB
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2017-08-25
- Last Posted Date
- 2020-03-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 58
- Registration Number
- NCT03262740
- Locations
- 🇺🇸
Miami Research Associates, South Miami, Florida, United States
🇺🇸PRA Health Sciences, Salt Lake City, Utah, United States
A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation
- Conditions
- Inflammatory Bowel DiseasesSystemic Lupus ErythematosusArthritic PsoriasisPsoriasis
- Interventions
- Drug: BMS-986165 CapsuleDrug: BMS-986165 Tablet
- First Posted Date
- 2017-08-18
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 49
- Registration Number
- NCT03254784
- Locations
- 🇺🇸
PRA Health Sciences, Lenexa, Kansas, United States
An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus
- First Posted Date
- 2017-08-17
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 363
- Registration Number
- NCT03252587
- Locations
- 🇺🇸
Local Institution - 0022, Decatur, Georgia, United States
🇺🇸Local Institution - 0023, El Cajon, California, United States
🇺🇸Little Rock Diagnostic Clinic, Little Rock, Arkansas, United States
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
- Conditions
- CancerTumorsNeoplasmMalignancy
- Interventions
- Drug: BMS-986226Biological: IpilimumabBiological: NivolumabBiological: Tetanus Vaccine
- First Posted Date
- 2017-08-16
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 80
- Registration Number
- NCT03251924
- Locations
- 🇺🇸
Local Institution - 0001, Philadelphia, Pennsylvania, United States
🇺🇸Local Institution - 0012, Saint Louis, Missouri, United States
🇺🇸Local Institution - 0002, Hackensack, New Jersey, United States
Pharmacokinetics and Metabolism Study in Healthy Male Participants
- Conditions
- Cancer
- Interventions
- Drug: BMS-986205
- First Posted Date
- 2017-08-11
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 9
- Registration Number
- NCT03247283
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States
A Study of BMS-986195 in Healthy Male Subjects
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2018-01-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT03245515
- Locations
- 🇳🇱
Local Institution, Groningen, Netherlands
A Study of Safety, Tolerability, and the Effects Two ND-L02-s0201 Have on the Body
- Conditions
- Fibrosis
- Interventions
- Drug: ND-L02-s0201
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2017-08-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 12
- Registration Number
- NCT03241264
To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants
- Conditions
- Thrombosis
- Interventions
- Drug: BMS-986177Other: Matched Placebo
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2018-06-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 33
- Registration Number
- NCT03224260
- Locations
- 🇺🇸
West Coast Clinical Trials, Anaheim, California, United States
A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2017-07-12
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 719
- Registration Number
- NCT03215706
- Locations
- 🇺🇸
Local Institution - 0091, Wichita, Kansas, United States
🇺🇸Local Institution - 0004, Lexington, Kentucky, United States
🇦🇺Local Institution - 0086, Gosford, New South Wales, Australia
Pharmacokinetics and Metabolism of [14C] BMS-986231 in Healthy Male Participants
- First Posted Date
- 2017-07-07
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 5
- Registration Number
- NCT03210909
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States